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Abstract
Introduction
The US Preventive Services Task Force recommends aspirin use
for men aged 45 to 79, when the potential benefit of preventing
myocardial  infarctions  outweighs  the  potential  harm  of
gastrointestinal hemorrhage. We determined prevalence and pre-
dictors of aspirin use for primary prevention of myocardial infarc-
tion vis-à-vis risk among men aged 45 to 79 in North Carolina.
Methods
The study used data for men aged 45 to 79 without contraindica-
tions to aspirin use or a history of cardiovascular disease from the
2013 North Carolina Behavioral Risk Factor Surveillance System
survey. Stratification by risk of myocardial infarction was based
on history of diabetes, high cholesterol, high blood pressure, and
smoking. Analyses were performed in Stata version 13.0 (Stata-
Corp LP); survey commands were used to account for complex
sampling design.
Results
Most  respondents,  74.2%  (95%  confidence  interval  [CI],
71.2%–77.0%), had at least one risk factor for myocardial infarc-
tion.  Prevalence  of  aspirin  use  among  respondents  with  risk
factors  was 44.8% (95% CI,  41.0–48.5)  and was significantly
higher than the prevalence among respondents without risk factors
(prevalence ratio: 1.44 [95% CI, 1.17–1.78]). No significant lin-
ear dose (number of risk factors)–response (taking aspirin) rela-
tionship was found (P for trend = .25). Older age predicted (P =
.03) aspirin use among respondents with at least one myocardial
infarction risk factor.
Conclusion
Most men aged 45 to 79 in North Carolina have at least one risk
factor for myocardial infarction, but less than half use aspirin. In-
terventions aimed at boosting aspirin use are needed among at-risk
men in North Carolina.
Introduction
Myocardial infarction (MI) is responsible for 5.4% of all deaths
among US men (1). In North Carolina, about 5.6% of men have
had a heart attack and about 45 per 100,000 die from acute MI
each year (2,3). Black non-Hispanic men in North Carolina are
about 30% more likely to die and approximately 5% more likely to
be hospitalized for MI than white non-Hispanic men.
Evidence supports aspirin use for primary prevention of cardiovas-
cular disease (CVD) events, including MI (4,5). In 2009, the US
Preventive Services Task Force (USPSTF) recommended aspirin
for primary prevention of MI in men aged 45 to 79 years, when
the potential  benefit  (reduction in MI) outweighs the potential
harm of gastrointestinal hemorrhage (6). The US Department of
Health and Human Services’ Million Hearts campaign promotes
appropriate aspirin therapy for those who would benefit from its
use as one component of the ABCS (aspirin use, blood pressure
control, cholesterol management, and smoking cessation) of heart
disease and stroke prevention (5).
Despite  the  USPSTF  recommendation,  physicians  are  under-
prescribing aspirin to patients (7), and high-risk patients are under-
using aspirin for the primary prevention of MI (8–12).  To our
knowledge, no study has used national Behavioral Risk Factor
Surveillance System (BRFSS) or North Carolina BRFSS data to
assess aspirin use in the at-risk groups mentioned in the USPSTF
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recommendation. Our overall objective was to assess aspirin use
among men in North Carolina for whom aspirin is potentially be-
neficial, according to the USPSTF recommendation, to 1) determ-
ine the prevalence of aspirin use among men aged 45 to 79 years;
2) assess aspirin use by number of risk factors for  MI;  and 3)
identify predictors of aspirin use among men with risk factors for
MI. This study updates the public health literature on aspirin use
among subpopulations that may benefit from aspirin.
Methods
The  BRFSS  is  an  annual  standardized,  state-based,  random-
digit–dial telephone survey of the noninstitutionalized US popula-
tion and is described in detail elsewhere (13). To match the spe-
cifications of the 2009 USPSTF recommendation, we limited our
study population to male respondents of the 2013 North Carolina
BRFSS survey aged 45 to 79 years.
During the 2013 North Carolina BRFSS survey, some optional
modules, including the cardiovascular health module, which asks
about aspirin use, were administered to a random subsample (ap-
proximately half)  of  eligible  respondents.  The North Carolina
State Center for Health Statistics uses this method (a split-sample
questionnaire) to ensure data collection on multiple BRFSS op-
tional  modules  and state-added questions of  interest  to  public
health programs while keeping interview length within acceptable
limits (between 20 and 30 minutes) to minimize participant drop-
off  (unpublished  data,  NC  State  Center  for  Health  Statistics,
2013).  In  2013,  the  cardiovascular  health  module  was admin-
istered to 931 of a possible 2,094 male BRFSS respondents aged
45 to 79. Given that 240 of the 931 eligible respondents would
have been dropped from our study based on exclusion criteria
(Appendix A) and the statistical limitations (ie, low precision of
estimates, nonconvergence of models in regression analysis) of a
small sample (691 respondents), we assessed the feasibility and
validity of imputing response values for the cardiovascular health
module for the 1,163 participants to whom the module was not ad-
ministered. We verified that the distribution of all study covari-
ates of interest did not differ significantly (within 5%) between re-
spondents and nonrespondents of the cardiovascular health mod-
ule (Appendix B) before proceeding with imputation.  In other
words, we tested and determined that the mechanism of missing-
ness of our outcome was “missing at random” (14). This finding
meant that we could either ignore the missing outcomes or impute
the missing data and incur minimal bias. Covariates of interest
were hypertension, diabetes, cholesterol, smoking, sex, age, race/
ethnicity,  education,  health  status,  health  insurance  coverage,
health  access  limitation  due  to  cost,  time  since  last  medical
checkup, and body mass index. Imputation allowed us to maintain
an eligible study population of 2,094 respondents.
We excluded respondents with a self-reported contraindication to
aspirin use or a history of any CVD to limit the scope of the study
to aspirin use for primary prevention only. We considered parti-
cipants who denied aspirin intake and responded either “yes, not
stomach related” or “yes, stomach problems” to the cardiovascu-
lar health module question “Do you have a problem or health con-
dition that makes taking aspirin unsafe for you?” to have a con-
traindication to aspirin use. We determined history of CVD by a
yes response to at least one of the following items from the chron-
ic health conditions section of the BRFSS core: 1) “Has a doctor
or nurse, or other health professional ever told you that you had a
heart attack also called a myocardial infarction?”; 2) “Has a doc-
tor or nurse, or other health professional ever told you that you had
angina or coronary heart disease?”; and 3) “Has a doctor or nurse,
or other health professional ever told you that you had a stroke?”
Therefore, of the initial 2,094 eligible participants, 163 were ex-
cluded because of a self-reported contraindication to aspirin use,
and 367 participants were excluded because of a self-reported his-
tory of CVD, resulting in a final study sample of 1,564 respond-
ents (Figure 1).
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Figure 1.  Selection of  study participants,  North Carolina,  Behavioral  Risk
Factor Surveillance System, 2013. Abbreviation: CVH, cardiovascular health.
 
The primary outcome of interest, aspirin use, was ascertained by a
yes response to the question “Do you take aspirin daily or every
other day?” from the cardiovascular health module. The second-
ary outcome of interest, aspirin use for the prevention of MI, was
ascertained by a yes response to the question “Do you take aspirin
to reduce the chance of a heart attack?” from the cardiovascular
health module.
Using responses to the BRFSS core, we stratified respondents’ po-
tential risk of MI based on 4 modifiable risk factors: diabetes, high
cholesterol, high blood pressure, and smoking. We selected these
risk factors to match as much as possible the factors identified in
the online Coronary Heart Disease (CHD) Risk Calculator from
the Medical College of Wisconsin, which uses information from
the Framingham Heart Study to determine 10-year risk of develop-
ing CHD (15,16). We performed hypothetical risk assessments for
respondents of various ages in our sample using the CHD Risk
Calculator and determined that the presence of any one of the 4 se-
lected risk factors placed respondents in a risk stratum for which
the benefits of aspirin may outweigh the risk of gastrointestinal
bleeding, according to Figure 1 of the 2009 USPSTF recommend-
ation statement (6). We also performed dose–response analysis
and determined that prevalence of aspirin use did not vary with an
increasing number of risk factors. Therefore, we dichotomized risk
of MI and assumed that for participants who reported any one of
the risk factors,  the potential  benefit  of  reducing MI risk out-
weighed the potential harm of gastrointestinal bleeding.
For univariate analysis, we used descriptive and summary statist-
ics (means for continuous variables and proportions for categoric-
al variables). For bivariate analysis, we used survey-adjusted F
statistics as well as linear and log-binomial regression models to
assess the relationship between aspirin use and risk factors and po-
tential predictors. We considered as strong predictors all factors
associated with aspirin use at a significance level of P < .05 dur-
ing bivariate analyses and retained these factors for multivariate
regression. Our analyses were performed using Stata version 13.0
(StataCorp LP) and survey (svy) commands to account for the
complex sampling design of the BRFSS survey.
Results
Most study participants (75.7%) were aged 45 to 64 years and
either white non-Hispanic (72.7%) or black non-Hispanic (19.3%);
85% of respondents reported having health insurance coverage,
and  74.5% reported  having  seen  a  health  care  provider  for  a
routine medical checkup within the previous 12 months (Table 1).
Almost 75% of respondents had one or more risk factors for MI:
33.8% had one risk factor, 28.2% had 2 risk factors, and 12.2%
had 3 or 4 risk factors (Table 1). Forty-eight percent of respond-
ents had hypertension, 48.3% had high cholesterol, 21.1% were
current smokers, and 15.5% had diabetes. The prevalence of aspir-
in  use  in  the  overall  study  sample  was  41.2%  (95%  CI,
38.1%–44.4%)  (Table  2).  Of  those  who  were  taking  aspirin,
87.8% (95% CI, 83.6%–91.0%) said they were taking aspirin to
prevent  heart  attacks  or  MI.  Except  for  current  smoking,  risk
factors for MI were independently associated with higher preval-
ence of aspirin use (Table 2).
The prevalence of aspirin use among men with one, 2, or 3 or 4
risk factors was significantly greater than among those with no
risk factors;  however,  we found no significant  linear dose–re-
sponse relationship between number of risk factors and aspirin use
(P for trend = .25) (Figure 2). When risk of MI was dichotomized,
the prevalence of aspirin use among respondents with one or more
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risk factors was 44.8% (95% CI, 41.0%–48.5%) and was signific-
antly higher than the prevalence among respondents with no risk
factors (prevalence ratio = 1.44; 95% CI, 1.17–1.78) (Table 2).
Age was a positive predictor of aspirin use among respondents
with one or more risk factors (Table 3).
Figure  2.  Weighted  prevalence  of  aspirin  use  by  number  of  myocardial
infarction risk factors among men aged 45 to 79 years in North Carolina,
Behavioral  Risk  Factor  Surveillance  System,  2013.  Risk  factors  were
hypertension, diabetes, smoking, and high cholesterol. Error bars represent
95% confidence intervals.
 
Discussion
The USPSTF recommended aspirin use for the primary preven-
tion of MI for men aged 45 to 79 years without contraindications
to aspirin, when the benefits outweigh the risks in a context of pa-
tient–provider shared decision making. In our study sample, des-
pite three-quarters of respondents having at least one risk factor
for MI, the prevalence of aspirin use was below 50% both in the
overall  sample  and  among  respondents  with  at  least  one  risk
factor. The prevalence rates of aspirin use in our study are slightly
lower than those of another study, which found a 50% to 60% pre-
valence of aspirin use among men aged 45 to 79 in Oklahoma with
risk factors for CVD (17). However, when compared with other
studies that did not restrict their study populations to the sex and
age groups for which aspirin may have benefits, our prevalence es-
timates are higher.  For example,  one study using BRFSS data
from 24 states reported an adjusted prevalence of 32.7% for aspir-
in use among men and women aged 35 years or older (18). This
finding suggests that reporting on aspirin use among the general
adult population or among sex and age groups for which there is
no clear evidence of the benefits, as is true for most studies using
BRFSS data, understates the prevalence of aspirin use among pop-
ulations that may benefit most from it. Even though the BRFSS
cardiovascular health module may be administered to a broad age
range of respondents, results should be reported specifically for
groups for which there is evidence of the benefits of aspirin, such
as men aged 45 to 79 years at risk for MI.
Our finding of low aspirin use among high-risk men also mirrors
the findings of Mainous and colleagues (19). They analyzed Na-
tional Health and Nutrition Examination Survey data to examine
aspirin use for both primary and secondary prevention of CVD
and found underutilization. This study and ours could benefit from
having clinical data to determine the degree to which health care
providers are recommending aspirin and to identify clinical de-
cision-support tools that might increase aspirin use for appropriate
high-risk patients (19).
Most respondents (87.8%) in our study sample said they were tak-
ing aspirin to prevent heart attacks, but 80% also said they were
taking aspirin to prevent  stroke.  This  finding suggests  limited
knowledge among study participants of the benefits of aspirin for
various risk groups, such as those mentioned in the 2009 USPSTF
recommendation. Health education interventions for both health
care providers and patients may prove useful in increasing know-
ledge of the benefits and risks of aspirin. Improved knowledge
may facilitate patient–provider shared decision making on aspirin.
For our study, the MI risk profile of participants, in conjunction
with the assertion of aspirin use, regardless of the intended use, is
sufficient in determining the potential benefit of taking aspirin for
MI prevention. Therefore, we used a yes response to the question
“Do you take aspirin  daily  or  every other  day?” to  define our
primary outcome rather than a yes response to the question “Do
you take aspirin to reduce the chance of a heart attack?”
Because most participants reported having health insurance and
having a routine medical checkup in the previous year, health sys-
tems can play a key role in improving aspirin use in this popula-
tion. High-risk respondents (those with at least one risk factor for
MI) who had health insurance were significantly more likely to be
taking aspirin than high-risk respondents who did not have insur-
ance. This difference indicates that access to health care has a pos-
itive effect on population aspirin use. Consequently, more needs to
be done to ensure that high-risk men see their health care pro-
viders for routine checkups, engage in patient–provider shared de-
cision making, and use aspirin and other applicable components of
the ABCS of heart disease and stroke prevention that are appropri-
ate for their risk. A 2005–2008 study of the National Ambulatory
Medical Care Survey and National Hospital Ambulatory Medical
Care Survey found low prescribing rates for aspirin among physi-
cians (46.9% of physicians prescribed aspirin for patients with
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ischemic vascular disease) and even lower prescribing rates in the
South (37.1%) (20). With aspirin now included in the list of med-
ications covered at no cost under the Affordable Care Act, shared
patient–provider decision making may be facilitated, more pro-
viders may prescribe aspirin, and more high-risk patients may use
it (21).
Although several strategies have been used successfully to in-
crease aspirin use, community-based interventions have improved
primary prevention efforts by bringing together primary care pro-
viders,  public  health  professionals,  and  community  resources
(22,23). In a recent 16-month intervention in Hibbing, Minnesota,
researchers used messaging on the use of aspirin for primary pre-
vention to increase aspirin use (24). Working with primary care
physicians in 3 health systems, they trained primary care health
professionals and identified aspirin-eligible candidates to receive
the messaging. Regular aspirin use increased from 36% at baseline
to 54% at 4 months and 62% at 16 months. This combined public
health–primary care approach may have the potential to improve
aspirin use for primary prevention.
Our study has several limitations. The results are limited by the in-
herent bias associated with self-reported survey data. Also, as a
result of methods changes in BRFSS in 2011 (25), we cannot com-
pare aspirin use before and after the USPSTF recommendation.
Furthermore, we could not more precisely quantify and stratify
risk of MI among participants because the BRFSS lacks clinical
and laboratory data on blood pressure and cholesterol levels that
would be needed for such calculations. Instead, we defined high
risk of MI simply by a self-reported history of diabetes, high cho-
lesterol,  high blood pressure,  or  current  smoking.  Finally,  the
strongly skewed distribution of respondents across categories of
potential predictors limited our ability to detect statistically signi-
ficant effects during bivariate and multivariate analyses.
The administration of the cardiovascular health module to a split
sample (about 50%) of the eligible BRFSS respondent population
had the potential to limit our study sample size. However, we de-
termined  that  our  outcome of  interest  was  missing  at  random
among nonrespondents of the cardiovascular health module. This
finding allowed us to impute missing responses and recover data
on respondents that would have otherwise been lost to analysis
(14). Notwithstanding our success in overcoming this potential
limitation, split-sample questionnaire administration is a limiting
factor to the sample size of all potential studies that rely on non-
core  BRFSS modules.  In  addition,  strict  statistical  conditions
(missing at random and missing completely at random) must be
met before imputation can be performed with minimal bias, and
imputation could be a statistically complex process (14). There-
fore, to eliminate this potential limitation, it may be worth consid-
ering administering the cardiovascular health module (and poten-
tially  all  other  noncore  modules)  to  the  entire  BRFSS sample
rather than to a split sample in future years.
Bertoni and colleagues estimated that North Carolina must have
30,000 fewer cases to meet the national Million Hearts objective
of  preventing  one  million  heart  attacks  and  strokes  by  2017
(26,27). Given the low aspirin use in our study sample and the ef-
fectiveness of aspirin in preventing MI among some men, increas-
ing aspirin use among high-risk men may be a useful component
toward achieving the Million Hearts goal for North Carolina.
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Tables
Table 1. Aspirin Use for Prevention of Myocardial Infarction Among Men Aged 45 to 79: General Characteristics of Study Popula-
tion (n = 1,564), Behavioral Risk Factor Surveillance System, North Carolina, 2013
Characteristic n Weighted % (95% CI)
Age, y
45–54 483 42.4 (39.1–45.7)
55–64 555 33.3 (30.4–36.3)
65–74 408 19.2 (17.0–21.6)
75–79 118 5.1 (4.1–6.4)
Race/ethnicity
White non-Hispanic 1,111 72.7 (69.7–75.6)
Black non-Hispanic 263 19.3 (16.7–22.2)
Hispanic 53 4.0 (2.9–5.3)
Other non-Hispanic 120 4.0 (3.0–5.3)
Education
Less than high school 192 15.6 (13.1–18.4)
High school 452 29.4 (26.6–32.5)
More than high school 918 55.0 (51.7–58.2)
General health status
Fair or poor 309 19.6 (17.2–22.3)
Good, very good or excellent 1,248 80.4 (77.7–82.8)
Health insurance coverage
No coverage at all 193 15.0 (12.7–17.5)
Some kind of coverage 1,365 85.0 (82.4–87.3)
Limited health care access due to cost
No 1,385 88.1 (85.8–90.0)
Yes 174 11.9 (10.0–14.2)
Last routine medical checkup
A year or more ago 342 25.5 (22.6–28.5)
Within the last 12 months 1,206 74.5 (71.5–77.4)
Body mass index (kg/m2)
Normal weight (18.0–24.9) 317 20.4 (17.9–23.2)
Overweight (25.0–29.9) 715 47.5 (44.2–50.8)
Obese (≥30.0) 486 32.1 (29.1–35.3)
Number of myocardial infarction risk factorsa
0 382 25.8 (23.0–28.8)
Abbreviation: CI, confidence interval.
a Risk factors were hypertension, diabetes, smoking, and high cholesterol.
(continued on next page)
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(continued)
Table 1. Aspirin Use for Prevention of Myocardial Infarction Among Men Aged 45 to 79: General Characteristics of Study Popula-
tion (n = 1,564), Behavioral Risk Factor Surveillance System, North Carolina, 2013
Characteristic n Weighted % (95% CI)
1 524 33.8 (30.8–36.9)
2 451 28.2 (25.4–31.2)
3 or 4 207 12.2 (10.2–14.5)
Abbreviation: CI, confidence interval.
a Risk factors were hypertension, diabetes, smoking, and high cholesterol.
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Table 2. Prevalence of Aspirin Use and Association Between Aspirin Use and Myocardial Infarction Risk Factors Among Men Aged
45 to 79 Years in North Carolina (n = 1,564), BRFSS, 2013
Subgroup na Weightedb Prevalence (%) of Aspirin Use (95% CI) Prevalence Ratio (95% CI)
Overall sample 1,564 41.2 (38.1–44.4)  —
Risk of myocardial infarctionc
Low risk 382 31.0 (25.0–37.0) 1.0 [Reference]
High risk 1,182 44.8 (41.0–48.5) 1.44 (1.17–1.78)
History of hypertension
No 766 36.2 (31.8–40.6) 1.0 [Reference]
Yes 798 46.6 (42.0–51.2) 1.29 (1.10–1.50)
History of diabetes
No 1,295 39.1 (35.7–42.6) 1.0 [Reference]
Yes 267 52.2 (44.1–60.4) 1.33 (1.12–1.59)
Current smoking
No 1,246 43.0 (39.4–46.6) 1.0 [Reference]
Yes 296 36.0 (28.9–43.1) 0.84 (0.68–1.04)
History of high cholesterol
No 711 37.2 (32.6–41.8) 1.0 [Reference]
Yes 712 46.7 (41.9–51.6) 1.26 (1.07–1.48)
Abbreviations: BRFSS, Behavioral Risk Factor Surveillance System; CI, confidence interval.
a Totals for some subcategories do not add to overall sample size (1,564) because of  missing data.
b Prevalence estimates are weighted to the overall population of men aged 45 to 79 in North Carolina using precalculated complex weight variables that are in-
cluded in the BRFSS dataset.
c Level of risk was dichotomized as high (≥1 risk factor) or low (no risk factors). Risk factors were hypertension, diabetes, smoking, and high cholesterol.
PREVENTING CHRONIC DISEASE VOLUME 12, E202
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY   NOVEMBER 2015
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
10       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2015/15_0342.htm
Table 3. Bivariate Analysis to Determine Predictors of Aspirin Use Among Men Aged 45 to 79 Years With at Least One Risk Factor
for Myocardial Infarction in North Carolina (n = 1,182), BRFSS, 2013
Predictor na
Weightedb Prevalence (%) of
Aspirin Use (95% CI) Prevalence Ratio (95% CI) P Valuec
Age, y
45–54 334 38.8 (32.1–45.5) 1.0 [Reference]
.03
55–64 433 47.3 (41.5–53.2) 1.22 (0.98–1.50)
65–74 324 52.2 (45.0–59.3) 1.34 (1.08–1.67)
75–79 91 43.6 (30.7–56.6) 1.12 (0.80–1.58)
Race/ethnicity
White non-Hispanic 830 53.1 (46.7–59.5) 1.0 [Reference]
.22
Black non-Hispanic 205 47.8 (34.3–61.2) 0.90 (0.66–1.22)
Hispanic 39 30.6 (9.0–52.1) 0.57 (0.28–1.17)
Other non-Hispanic 96 58.5 (35.8–81.2) 1.10 (0.73–1.65)
Education
Less than high school 153 42.9 (29.0–56.7) 1.0 [Reference]
.81High school 353 56.4 (46.8–66.0) 1.32 (0.91–1.89)
More than high school 674 51.4 (44.0–58.8) 1.20 (0.84–1.71)
General health status
Fair or poor 272 47.2 (39.8–54.7) 1.0 [Reference]
.47
Good, very good, or excellent 905 44.1 (39.8–48.4) 0.93 (0.77–1.12)
Health insurance coverage
No coverage at all 141 36.2 (26.6–45.7) 1.0 [Reference]
.06
Some kind of coverage 1,036 46.2 (42.2–50.2) 1.28 (0.97–1.68)
Limited healthcare access due to cost
No 1,039 44.5 (40.5–48.5) 1.0 [Reference]
.71
Yes 139 46.5 (36.3–56.8) 1.05 (0.82–1.33)
Last routine medical checkup
A year or more ago 208 40.4 (32.1–48.7) 1.0 [Reference]
.23
Within the last 12 months 961 46.2 (42.0–50.4) 1.14 (0.91–1.43)
Body mass index, kg/m2
Normal weight (18.0–24.9) 215 43.2 (30.5–55.9) 1.0 [Reference]
.33Overweight (25.0–29.9) 539 50.3 (42.3–58.2) 1.16 (0.83–1.62)
Obese (≥30.0) 400 56.5 (47.3–65.8) 1.31 (0.93–1.83)
Abbreviations: BRFSS, Behavioral Risk Factor Surveillance System; CI, confidence interval.
a Totals for some subcategories do not add to overall sample size (1,564) because of missing data
b Prevalence estimates are weighted to the overall population of men aged 45 to 79 in North Carolina using precalculated complex weight variables that are in-
cluded in the BRFSS dataset.
c P value for Pearson design–based F statistic obtained from survey-weighted cross tabulation of aspirin use and potential predictors.
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Appendix A. Sample Size Scenarios With and Without Imputation of Missing
Outcomes, North Carolina Behavioral Risk Factor Surveillance System, 2013
Characteristic No Imputation Imputation
Eligible study population (all male respondents aged 45–79 y) 2,094 2,094
Nonrespondents to cardiovascular health module (no data on outcome, ie, aspirin use) −1,163 0
Initial study population (respondents with data on aspirin use) 931 2,094
Exclusion criteria  no. 1: contraindication to aspirin −74 −163
Exclusion criteria  no. 2: history of cardiovascular disease −166 −367
Final study sample 691 1,564
At risk for myocardial infarctiona 518 1,182
a The primary focus of the study was aspirin use among men at risk of myocardial infarction; therefore, most of the analyses were done on this subset of the study
sample.
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Appendix B. Frequency Distribution of Key Variables Among Respondents and
Nonrespondents of the Cardiovascular Health Module, North Carolina Behavioral
Risk Factor Surveillance System, 2013
Covariates
Cardiovascular Health Module
Respondents, % Nonrespondents, %
Hypertension
Yes 45.6 44.2
No 54.4 55.8
Diabetes
Yes 15.1 14.9
No 84.9 85.1
High cholesterol
Yes 46.5 45.9
No 53.5 54.1
Current smoking
Yes 17.3 18.1
No 82.7 81.9
Sex
Female 62.2 60.0
Male 37.8 40.0
Age, y
<45 26.9 30.7
45–64 38.3 37.0
>64 34.8 32.3
Race/ethnicity
White 68.1 68.2
Black 19.2 18.9
Hispanic 5.2 5.2
Other 7.5 7.7
Education
<High school 13.5 16.5
High school 28.7 27.7
>High school 57.8 58.8
Health status
Fair or poor 23.1 22.1
Good, very good or excellent 76.9 77.9
Health insurance coverage
No coverage at all 14.7 14.9
(continued on next page)
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(continued)
Covariates
Cardiovascular Health Module
Respondents, % Nonrespondents, %
Some kind of coverage 85.3 85.1
Limited health care access due to cost
No 84.2 83.5
Yes 15.8 16.5
Last routine medical checkup
A year or more ago 19.8 21.9
Within the last 12 months 80.2 78.1
Body mass index, kg/m2
Normal weight (18.0 to 24.9) 30.9 33.3
Overweight (25.0 to 29.9) 37.5 35.6
Obese (≥30.0) 31.6 31.1
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